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Available online 5 April 2007Summary Oral lichen planus (OLP) is a chronic inflammatory disease of unknown origin, show-
ing little spontaneous regression. WHO classifies OLP as a premalignant condition, however, the
underlying mechanisms initiating development of cancer in OLP lesions are not understood. The
p53 tumour suppressor plays an important role in many tumours, and an increased expression of
p53 protein has been seen in OLP lesions. Recently it was shown that the human TP53 gene
encodes at least nine different isoforms. Another member of the p53 family, p63, comprises
six different isoforms and plays a crucial role in the formation of oral mucosa, salivary glands,
teeth and skin. It has also been suggested that p63 is involved in development of squamous cell
carcinoma of the head and neck (SCCHN). In contrast to p53, a decreased expression of p63 pro-
tein has been seen in OLP lesions. In this study, we mapped the expression of five novel p53
isoforms at RNA and protein levels in OLP and matched normal controls. In the same samples
we also measured levels of p63 isoforms using quantitative RT–PCR. Results showed p53 to
be expressed in all OLP lesions and normal tissues. The p53b and D133p53 isoforms were
expressed in the majority of samples whereas the remaining three novel isoforms analysed were
expressed in only a few samples. Levels of p63 isoforms were lower in OLP lesions compared
with normal tissue, however, changes were not statistically significant.c 2007 Elsevier Ltd.
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Oral lichen planus (OLP) is a chronic inflammatory disease of
skin and mucosa affecting approximately 1–2% of the adult
population. The disease occurs more frequently in women
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elderly than in young people.1 In contrast to lichen of the
skin, OLP seems to have a chronic cause with low tendency
to spontaneous regression and high resistance to topical
treatment.2 Despite numerous studies the origin remains
unknown. However, an autoimmune cause has been sug-
gested3 and we have recently demonstrated occurrence of
auto antibodies against p63 and p73 in sera from patients
diagnosed with OLP.4
OLP lesions have a higher cell turnover than normal tis-
sue5 and WHO classifies OLP as a premalignant condition
making ‘‘oral mucosa more sensitive to exogenous carcin-
ogens and thus to develop oral carcinoma’’.6 Malignant
transformation to squamous cell carcinoma has been seen
in 2–3% of OLP patients. Females with OLP run a 50% high-
er risk of developing squamous cell carcinoma of the head
and neck (SCCHN) compared to a control group.6 The
underlying mechanisms initiating development into SCCHN
have not been clarified, however, an association between
chronic inflammation and a variety of cancers is
known.7–9
Approximately two decades ago the p53 tumour suppres-
sor was discovered. Activation of p53 after DNA damage or
oncogenic signalling is an important protective mechanism
enabling DNA repair, induction of cell cycle arrest or apop-
tosis. Mutation within the human TP53 gene is found in
approximately half of all human tumours studied and a high
prevalence of TP53 mutations has been seen in patients
diagnosed with OLP, particularly females.10 We and other
investigators have previously shown an increased expression
of p53 protein in OLP lesions compared with normal tis-
sue.10–18
Recently it was shown that human p53 encodes at least
nine different isoforms through alternative splicing, alter-
native initiation sites for translation and the use of an
internal promoter: p53, p53b, p53c, D133p53, D133p53b,
D133p53c, D40p53, D40p53b and D40p53c.19 In the first
study of these novel p53 isoforms in SCCHN it was shown
that p53 variant mRNAs were expressed in both normal oral
epithelium and SCCHN. The most common of these isoforms
being p53b, which was detected in the majority of samples.
Of the other isoforms studied all but Dp53 could be de-
tected in at least some samples from tumour and normal
epithelium.20
The p53 relative p63 is encoded by a gene located on
chromosome 3q27–29. In humans this gene encodes six dif-
ferent isoforms: TAp63a, TAp63b, TAp63c, DNp63a, DNp63b
and DNp63c.21,22 p63 is essential for development of ecto-
dermal structures, and p63 / mice lack oral mucosa,
skin, teeth, hair follicles, salivary and mammary glands.23,24
The exact function of each individual isoform is, however,
not clear. It is known that each of the p63 proteins have dif-
ferent characteristics and functions, where some resemble
its relative the tumour suppressor protein p53, while others
have the opposite function.25 We have previously shown a
decreased expression of the different p63 proteins in OLP
lesions compared with normal oral mucosa.18 Concerning
RNA levels of the different isoforms, no data is as of today
available.
The aim of the present study was to clarify if the ob-
served increased expression of p53 protein seen in OLP le-
sions represents a mixture of the different novel p53isoforms or the original p53 isoform only. Furthermore
we wanted to see in the same samples, if there was any
correlation between RNA levels of the different p63 iso-
forms, and the decrease in protein expression that we
have previously seen in these lesions. In order to judge
whether OLP in this aspect resembles normal or tumour
tissue, normal matched control tissue was analysed in par-
allel, and results compared with data from analysis of
SCCHN.
Materials and methods
Patients and specimens
Two 4 mm punch biopsies were, after informed consent, ta-
ken from the buccal mucosa on 20 consecutive patients with
OLP referred to the specialist clinic at the department of
Odontology, Umea˚ University. All patients were clinically
and histologically diagnosed with oral lichen planus. Four-
teen were females with a mean age of 63.5 (range 42–78)
and six were males with a mean age of 59.5 (range 48–
75). Biopsies were also collected from twenty sex and age
matched healthy controls. All samples were immediately
frozen and stored at 80 C. Permission for the study hade
been granted by the Ethical Committee at Umea˚ University
(dnr 05-010 M).RNA extraction
One of the frozen biopsies was cut into pieces in a Petri
dish placed on dry ice and transferred into a 1.5 ml tube
containing 250 ll TRIzol reagent (Invitrogen). Samples
were homogenized using a pellet mixer (MARCK Eurolab),
a further 750 ll of TRIzol added and samples incubated
at room temperature for 5 min. Mixtures were then centri-
fuged for 15 min at 13,000 rpm at 4 C. The upper liquid
phase was moved to a new tube, diluted with an equal
amount of isopropyl alcohol, incubated for 10 min and
again centrifuged for 10 min at 4 C. The upper layer was
carefully removed and pellets washed in 70% ethanol be-
fore drying and dissolved in DePc-H2O by pipetting 10–20
times, heated to 60  C for 10 min and pipetted another
10–20 times. Extracted RNA was then kept at 80 C until
use.cDNA synthesis and RT–PCR for analysis of p53
isoforms
cDNA was synthesized using a Cloned AMW First-Stand cDNA
Synthesis kit (Invitrogen) according to the manufacturers
instructions. One microgram of RNA was added into a total
reaction volume of 20 ll. The cDNA was amplified in two
rounds of PCR (nested PCR) in order to detect the different
isoforms of p53. The following p53-specific primer sets were
used: for the first PCR-round of p53, p53b, and p53c: e2.1/
RT1. For D133p53, D133p53b, and D133p53c: i4f1/ RT2
were used. For the nested PCR the primers for p53 were:
e2/RT2; for p53b: e2/p53b; for p53c: e2/p53g; for
D133p53: i4f2/RDNp53; for D133p53b: i4f2/p53b, and for
D133p53c: i4f2/p53g.
Primer sequences : e2:1 ð50-GTCACTGCCATGGAGGAGCCGCA-30Þ
e2 ð50-ATGGAGGAGCCGCAGTCAGAT-30Þ
i4f1 ð50-CTGAGGTGTAGACGCCAACTCTCTCTAG-30Þ
i4f2 ð50-GCTAGTGGGTTGCAGGAGGTGCTTACAC-30Þ
RT1 ð50  GACGCACACCTATTGCAAGCAAGGGTTC-30Þ
RT2 ð50-AATGTCAGTCTGAGTCAGGCCCTTCTGTC-30Þ
p53b ð50-TTTGAAAGCTGGTCTGGTCCTGA-30Þ
p53g ð50-TCGTAAGTCAAGTAGCATCTGAAGG-30Þ
RDNp53 ð50-CTCACGCCCACGGATCTGA-30Þ
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30 s, 60 C for 45 s and 72 C for 90 s. PCR products were
loaded on a 1% agarose gel.19 All samples were done in
duplicate and most of them in triplicate, and considered po-
sitive when positive in all replicates, or positive/variable
when isoforms were detected in at least one PCR run.
Quantitative PCR for analysis of p63 isoforms
Quantitative RT–PCR for analysis of p63 isoforms was per-
formed using a human p63/b-actin multi-parametric kit
(Search LC, Heidelberg, Germany) and analysed on a Light-
cyclerTM from Roche. In brief, cDNA was diluted 12 times
and thenmixedwith the different primer sets to amplify each
of the p63 splice variant mRNAs individually and, simulta-
neously amplify b-actin to serve as an internal control for
cDNA integrity and relative cDNA quantity in the different tis-
sue samples. Primers were selected to bridge intronic
sequences in order to discriminate between amplification of
cDNA and contaminating genomic DNA. Reactions were ana-
lysed on the LightcyclerTM with one denaturation cycle, 50
amplification cycles, one melting curve analysis cycle, and,
finally, one cooling cycle. Reactions were run in duplicate,
and a mean value of the two samples was calculated.26
Statistical analysis
For analysis of p63 mRNA levels in OLP lesions and corre-
sponding clinically normal oral mucosa an independent sam-
ples T-test was performed using Computer software SPSS
version 12.0.
Protein extraction
From one frozen biopsy protein was extracted using a Micro-
dismembrator (B. Braun. Biotech International) for pulveriz-
ing the sample. One hundred microliter of lysis buffer con-
taining 0.5% NP-40, 0.5% Na-doc, 0.1% SDS, 150 mM NaCl,
50 mM Tris pH 7.5, 1 mM EDTA, 1 mM NaF and protease
inhibitor cocktail (Sigma-Aldrich Chemie, Steinheim, Ger-
many) was added and the pulverized samples homogenized.
Protein concentrations were determined using BCA Protein
Assay Kit (Pierce, Rockford, IL, USA).
Immunoblot analysis and quantification
Bio-Rad PROTEAN II xi Œ XL Vertical Electrophoresis system
or vertical mini-gels were used according to the user man-ual. Thirty microgram of protein was mixed with 2· loading
buffer, boiled for 10 min and electrophoresed on 10% SDS-
polyacrylamide gels. Proteins were transferred to nitrocel-
lulose membranes (Hybond ECL, Amersham Biosciences, Lit-
tle Chalton, NA, USA) and stained with ponceau red for
evaluation of transfer efficiency and loading. Membranes
were blocked in 5% milk with 0.4% Tween in 1X PBS, and
antibodies diluted in the same blocking solution. Primary
antibodies used in this study were DO-1 for detection of
p53, p53b, p53c.27, and DO-12 for detection of p53, p53b,
p53c, D133p53, D133p53b, D133p53c, D40p53, D40p53b,
and D40p53c isoforms.28
Results
Expression of p53 isoforms using RT–PCR
By the use of RT–PCR, six different p53 isoforms could be
amplified from OLP tissue as well as normal tissue: p53,
p53b, p53c, D133p53, D133p53b, and D133p53c. All samples
were analysed as matched pairs, meaning that one OLP le-
sion and corresponding matched control were analysed in
parallel, though coded, as to hide which sample was lesion
and which was control. p53 mRNA could be detected in rep-
licate analyses of all but 1 of the 20 OLP samples as well as
all but 1 of the 20 controls. These two samples were positive
in one analysis, but negative in the other. The majority of
OLP and control samples also expressed the p53b and
D133p53 isoforms in at least one of the replicate analyses.
Expression of p53c, D133p53b and D133p53c was, however,
limited to only a few samples. In general the novel p53 iso-
forms studied were detected in fewer OLP samples com-
pared to matched controls (Fig. 1).
Expression of p63 isoforms
Using quantitative RT–PCR analysis of p63 showed that p63a
had highest and DNp63 second highest level of all p63
mRNAs. TAp63 had lowest levels in both OLP and corre-
sponding normal tissue. For all isoforms individual variations
could be seen (results not shown). Results also showed a
general decrease in levels of p63 isoforms in OLP compared
to normal tissue. The most pronounced decrease seen in
expression of p63c, p63a and DNp63 (P = 0.116; 0.187 and
0.205, respectively). The level of TAp63 was unchanged
while a slight reduction in p63b was found in OLP lesions
compared to normal tissue. None of these changes were,
however, statistically significant (Fig. 2).
Figure 1 Results from nested RT–PCR analysis of six p53 isoforms. Bars show percentage of positive samples. In total 40 samples
were analysed, 20 OLP lesions and 20 sex and aged matched normal tissues. P53 mRNA was detected in all OLP lesions and normal
tissue, either in all replicates analysed (positive) or in one or two of the replicates (positive/variable). Of the five novel p53 isoforms
analysed, p53b and D133p53 were detected in the majority of samples, while the remaining three novel isoforms only were detected
in a few samples.
Figure 2 Quantitative RT/PCR of the different p63 isoforms in OLP lesions and controls. Black bars represent OLP lesions and
white bars normal controls. Results are expressed as mean for all samples analysed in each group and are based on the relative
amount of p63 RNA for each sample analysed adjusted for the level of internal control amplification (b-actin) obtained for each
sample. The most pronounced decrease was seen in levels of DNp63, p63a and p63c. Levels of TAp63 were basically unchanged when
comparing OLP lesions and controls, while a slight reduction in p63b was seen in OLP. Note that different scales are used for the two
groups TAp63, p63b, p63c and DNp63, p63a, respectively.
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In order to detect different p53 isoforms also at protein
levels, two antibodies were used. DO-1 recognising an epi-
tope located at amino acids 20–25, and therefore not rec-
ognising the N-terminal truncated D133p53 or D40p53
isoforms and DO-12 recognising the p53, p53b, p53c,
D133p53, D133p53b, D133p53c, D40p53, D40p53b, and
D40p53c isoforms.20 All samples were run in duplicate and
results showed detectable levels of p53 protein in only
one of the OLP samples. This protein had an identical
molecular weight to p53 and bands that might represent
p53-isoforms were not detected (data not shown).Discussion
Increased expression of the p53 tumour suppressor protein
has been seen in studies of oral lichen planus, simulta-
neously with a decreased expression of its sibling p63.10–18
With the discovery of several novel p53 isoforms we there-
fore wanted to see if this increased expression of p53 pro-
tein in fact represented different isoforms which could be
important in OLP lesions. By using RT/PCR we could detect
three of the isoforms in the majority of OLP and control
samples, whereas the remaining three isoforms were de-
tected in only a few samples. In a previous study of p53 iso-
forms in SCCHN we have shown that the method used,20
160 M. Ebrahimi et al.nested RT/PCR, is very sensitive and identifies extremely
low levels of mRNA. This was clearly shown when comparing
RT/PCR results with just one single round of PCR. Using the
single round PCR only the p53, p53b and D133p53 isoforms
were detected.20 These three isoforms were also the ones
that could be amplified in the majority of our samples.
The inconsistencies seen between replicates of the same
samples, using different batches of cDNA, is, as in the study
of SCCHN, compatible with low levels of the novel p53 iso-
form mRNAs. Also, based on the comparatively higher incon-
sistency in amplification of the p53b and D133p53 isoforms
seen in this study, we suggest that levels of these isoforms
are in fact much lower in OLP lesions compared to tumour-
and clinically normal tumour adjacent tissue in patients
with SCCHN. This could in turn indicate a more tumour re-
lated role for these isoforms. The fact that we in the pres-
ent study used three times as much RNA for cDNA synthesis,
1 lg of total RNA compared to 300 ng from the tumours, fur-
ther supports the theory that levels of the novel p53 iso-
forms really are lower in OLP lesions compared to SCCHN.
By using immunoblotting and antibodies detecting p53/
p53b/p53c and all isoforms analysed respectively, only the
p53 protein could be detected in one of the OLP samples,
whereas around half of the tumours and a little fewer of
the normal tumour adjacent tissue had detectable levels
of p53 protein.20 However, none of the novel p53 proteins
were expressed at detectable levels in the present or previ-
ous study. It should be kept in mind that wild type p53, and
maybe also these novel isoforms, is predominantly regu-
lated by post-translational mechanisms, and therefore a di-
rect correlation to RNA levels cannot be expected.29
However, with the reagents available today, none of the no-
vel isoforms could be detected. Other possible explanations
could be short half life of the isoforms, in concordance with
wild type p53, or tissue specific expression. In the latter
case translation of RNA is dependent on tissue specific
cofactors and with these absent, RNA is not translated into
protein.
For the p53 sibling p63 we could see a down regulation of
all isoforms at the RNA level in OLP lesions, though not sig-
nificant. This is in clear contrast to SCCHN tumours where
levels of all isoforms were upregulated compared to clini-
cally normal tumour adjacent tissue. Levels of p63b and
DNp63 further showed a statistically significant upregula-
tion.26 In OLP lesions levels of the TAp63 isoforms were un-
changed compared to the controls (0.0010 versus 0.0011). A
discrepancy between RNA and protein levels for the TA iso-
form specifically has been shown previously, for example in
psoriasis lesions.30
As chronic inflammation is known to cause DNA damage,
the decreased levels of p63 seen in the chronic inflamma-
tory condition OLP are comparable to changes seen in epi-
thelia after exposure to UV light. In this DNA damaged
epithelia decreased DNp63 expression is needed for induc-
tion of apoptosis.31 This may, as previously suggested, indi-
cate a protective mechanism enabling removal of DNA
damaged cells in OLP.18
In conclusion, we have been able to detect RNA of 3 p53
isoforms in the majority of OLP lesions and normal controls
analysed. Two of these belong to the group of recently de-
tected novel p53 isoforms. The function of these novel iso-
forms is, so far, not known but the same isoforms have alsobeen amplified in samples of SCCHN, at seemingly higher
levels. This could indicate a more tumour related role for
these isoforms. None of them could, however, be detected
at protein level with the reagents available today. There-
fore, in order to clarify the role of these novel p53 isoforms
in OLP lesions, further studies with preferably more isoform
specific reagents are needed.Conflict of interest statement
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